As the payments and healthcare industries move further into 2026, medispa operators, health and wellness clinics, and medical weight loss providers continue to experience sudden payment account terminations from Square. These shutdowns most frequently affect businesses offering prescription based weight loss treatments such as semaglutide, tirzepatide, and other GLP 1 medications.
Many of these merchants report the same pattern. Their Square account functions normally for months or even years. Transactions settle without issue. Then, following a routine review or automated monitoring update, the account is frozen or terminated with minimal explanation.
For clinics relying on recurring payments, patient subscriptions, or high volume card transactions, this type of disruption can immediately impact cash flow and patient care.
The core issue is not merchant behavior. It is Square’s business model.
Square does not support high risk medical weight loss merchants, and heading into 2026, the platform continues to narrow its acceptable use policies as card brand enforcement and regulatory pressure increase.
At Corepay, we work with health and wellness businesses every day and regularly help clinics regain stable payment processing after being terminated by Square or other payment aggregators.
*See our medspa payment processing here.
Key Takeaways for 2026
Medical weight loss merchants are facing stricter underwriting and monitoring requirements
Square continues to prohibit prescription based weight loss services
GLP 1 clinics require true high risk underwriting rather than aggregator approval
Payment aggregators are exiting regulated healthcare verticals
Corepay remains a stable Square alternative for compliant health and wellness businesses
Understanding Square’s Payment Model
To understand why these terminations are happening, it is important to understand how Square operates.
Square is a payment aggregator. This means merchants are not individually underwritten with a dedicated acquiring bank. Instead, Square pools thousands of businesses under a shared merchant account structure.
This model works well for low risk retail, food service, and basic service businesses. It does not work well for regulated or high risk industries.
Because Square absorbs risk across the entire pool, it must remove any business type that increases exposure to chargebacks, disputes, regulatory complaints, or card brand scrutiny. Medical weight loss businesses fall squarely into that category.
In 2026, Square’s acceptable use policies continue to exclude:
Prescription based medical services
Clinics prescribing or facilitating access to GLP 1 medications
Outcome dependent healthcare services
Businesses with elevated dispute potential
Even clinics operating fully within legal and medical guidelines are impacted once Square’s monitoring systems identify the underlying business activity.
Why Square Is Terminating Health and Wellness Accounts
Square’s terminations are not random. They are driven by a combination of automated monitoring, card brand expectations, and internal risk tolerance.
Several factors are contributing to the increase in shutdowns going into 2026.
- Prescription based weight loss treatments are classified as high risk
- Patient dissatisfaction can lead to disputes unrelated to fraud
- Chargebacks tied to medical outcomes are difficult to defend
- Regulatory guidance around GLP 1 medications continues to evolve
- Advertising and marketing claims are closely scrutinized
Once Square identifies prescription weight loss activity, the account is typically flagged during ongoing monitoring. In most cases, the termination is permanent and funds may be held temporarily while disputes settle.
This is why many clinics are surprised. Initial approval does not mean long term support.
The Role of Card Brand Risk Programs in 2026
Card networks are playing a larger role in merchant risk management than ever before.
Programs such as Visa VAMP, Visa VIRP, Mastercard monitoring standards, and enhanced scam and healthcare enforcement initiatives have increased expectations for acquiring banks.
These programs place pressure on acquirers to reduce exposure to:
- High chargeback ratios
- Elevated refund volumes
- Consumer complaints
- Regulated medical claims
Aggregators like Square respond by tightening policies and removing entire verticals rather than managing risk on a merchant by merchant basis.
This trend is expected to continue throughout 2026 and beyond.
What Makes Weight Loss Injections High Risk in 2026
Medical weight loss is not considered high risk because it is illegitimate. It is considered high risk because of how banks evaluate liability and consumer protection exposure.
Key risk factors include:
- Prescription medications subject to changing FDA and clinical guidance
- Potential adverse reactions and side effects
- Patient dissatisfaction related to expectations or results
- Recurring billing models tied to treatment plans
- Medical advertising restrictions and claim sensitivity
From a payment processor’s perspective, disputes tied to medical services are difficult to resolve. Cardholders may dispute charges months after treatment based on outcomes, not transaction validity.
These disputes are challenging to defend even when the clinic has done nothing wrong.
Why Reapplying to Other Aggregators Is a Mistake
After being terminated by Square, many merchants attempt to sign up with other aggregators such as Stripe, PayPal, or similar platforms.
This often creates additional problems.
Repeated applications across aggregators can generate internal risk signals that follow the business. Each rejection increases the likelihood of future denials.
In some cases, merchants unknowingly trigger monitoring databases that complicate future underwriting with legitimate acquiring banks.
For medical weight loss clinics, aggregator hopping rarely solves the problem. It simply delays the inevitable.
What To Do If Square Terminates Your Account
If Square terminates your account, speed and strategy matter.
The first step is to stop processing immediately and review any communications regarding fund holds or dispute timelines.
Next, clinics should seek out payment processors that specialize in high risk healthcare and understand medical weight loss underwriting.
When evaluating a processor, it is important to confirm that they:
- Explicitly support prescription based weight loss clinics
- Understand GLP 1 compliance and healthcare regulations
- Offer dedicated acquiring relationships
- Provide dispute and chargeback management tools
- Are transparent about pricing and reserves
At Corepay, our underwriting process is designed to prevent surprise shutdowns by aligning merchant activity with acquiring bank expectations from the start.
Why Traditional Processors Decline GLP 1 Clinics
Many clinics are confused when traditional processors decline their applications even after Square termination.
This is because most low risk processors are not equipped to underwrite medical weight loss businesses. They lack the compliance frameworks, monitoring tools, and risk tolerance required.
As card brand enforcement increases, more processors are choosing to exit healthcare adjacent verticals entirely.
This leaves a smaller group of specialized high risk processors supporting the space.
Why Choose Corepay for Weight Loss Payment Processing
Corepay was built to support regulated and high risk industries that aggregators and traditional processors avoid.
We work extensively with:
Medical weight loss clinics
Medispa operators
Telemedicine platforms
Health and wellness businesses with prescription services
Our approach focuses on long term stability rather than short term approval.
Corepay Payment Processing Capabilities for 2026
When working with Corepay, medical weight loss merchants gain access to:
Pricing structured for high risk healthcare verticals
Fast approvals, often within 24 to 72 hours
Support for high volume and recurring billing models
The Netvalve payment gateway built for high risk transactions
Multi currency and international payment acceptance
PCI Level 1 compliant infrastructure
Dedicated account management
Chargeback mitigation tools including CB Alert
Unlike aggregators, Corepay provides merchants with dedicated acquiring relationships and proactive risk management.
Chargeback Protection for Weight Loss Clinics
Chargebacks remain one of the biggest risks for medical weight loss businesses.
In 2026, processors and banks expect merchants to actively manage disputes, not simply react to them.
Corepay helps clinics reduce chargebacks through:
- Clear billing descriptor setup
- Refund and cancellation strategy guidance
- Early dispute alerts
- Evidence support for representment
- Tools designed to align with card brand standards
This proactive approach helps protect merchant accounts and long term processing relationships.
Final Thoughts for 2026
If your clinic offers semaglutide, tirzepatide, or other GLP 1 treatments, Square is no longer a viable long term payment solution.
This is not a temporary policy shift. It reflects a broader industry move away from aggregators supporting regulated healthcare services.
The good news is that reliable, compliant payment processing is still available. It simply requires working with a processor that understands high risk healthcare and is built to support it.
